[1] KONSTAN M W,RATJEN F.Effect of dornase alfa on inflammation and lung function:potential role in the early treatment of cystic fibrosis[J].J Cyst Fibros,2012,11(2):78-83.
[2] AMIN R,SUBBARAO P,LOU W,et al.The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis[J].Eur Respir,2011,37(4):806-812.
[3] CONRAD C,LYMP J,THOMPSON V,et al.Long-term treatment with oral N-acetylcysteine:affects lung function butnotsputum inflammation in cystic fibrosis subjects.A phase Ⅱ randomized placebo-controlled trial[J].J CystFibros,2015,14(2):219-227.
[4] ELKINS M R,ROBINSON M,ROSE B R,et al.A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis[J].N Engl J Med,2006,354(3):229-240.
[5] BUONPENSIERO P,De GREGORIO F,SEPE A,et al.Hyaluronic acid improves "pleasantness" and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis[J].Adv Ther,2010,27(11):870-878.
[6] FURNARI M L,TERMINI L,TRAVERSO G,et al.Nebulized hypertonic saline containing hyaluronic acid improves tolerability in patients with cystic fibrosis and lung disease compared with nebulized hypertonic saline alone:a prospective,randomized,double-blind,controlled study[J].Ther Adv Respir Dis,2012,6(6):315-322.
[7] ROS M,CASCIARO R,LUCCA F,et al.Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients:a multicenter,randomized,controlled clinical trial[J].Aerosol Med Pulm Drug Deliv,2014,27(2):133-137.
[8] AITKEN M L,BELLON G,De BOECK K,et al.Long-term inhaled dry powder mannitol in cystic fibrosis:an international randomized study[J].Am J Respir Crit Care Med,2012,185(6):645-652.
[9] BILTON D,DAVISKAS E,ANDERSON S D, et al.Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis[J].Chest,2013,144(1):215-225.
[10] ACCURSO F J,MOSS R B,WILMOTT R W,et al.Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function[J].Am J Respir Crit Care Med,2011,183(5):627-634.
[11] RATJEN F,DURHAM T,NAVRATIL T,et al.Long term effects of denufosol tetrasodium in patients with cystic fibrosis[J].J Cyst Fibros,2012,11(6):539-549.
[12] MOGAYZEL P JJr,NAURECKAS E T,ROBINSON K A,et al.Cystic fibrosis pulmonary guidelines.Chronic medications for maintenance of lung health[J].Am J Respir Crit Care Med,2013,187(7):680-689.
[13] LANGTON HEWER S C,SMYTH A R.Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis[J].Cochrane Database Syst Rev,2014(11):CD004197.
[14] TRAPNELL B C,MCCOLLEY S A,KISSNER D G,et al.Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection[J].Am J Respir Crit Care Med,2012,185(2):171-178.
[15] WATERS V,RATJEN F.Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis[J].Cochrane Database Syst Rev,2014(12):CD010004.
[16] LANDS L C,STANOJEVIC S.Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis[J].Cochrane Database Syst Rev,2013(6):CD001505.
[17] BALFOUR-LYNN I M,LEES B,HALL P,et al.Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis[J].Am J Respir Crit Care Med,2006(173):1356-1362.
[18] RAMSEY B W,DAVIES J,McELVANEY N G.A CFTR potentiator in patients with cystic fibrosis and the G551d mutation[J].N Engl J Med,2011,365(18):1663-1672.
[19] DAVIES J C,WAINWRIGHT C E,CANNY G J,et al.Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551d mutation[J].Am J Respir Crit Care Med,2013,187(11):1219-1225.
[20] De BOECK K,MUNCK A,WALKER S,et al.Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation[J].J Cyst Fibros,2014,13(6):674-680.
[21] CLANCY J P,ROWE S M,ACCURSO F J,et al.Results of a phase Ⅱa study of VX-809,an investigational CFTR corrector compound,in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation[J].Thorax,2012,67(1):12-18.
[22] FLUME P A,LIOU T G,BOROWITZ D S,et al.Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation[J].Chest,2012,142(3):718-724.
[23] WAINWRIGHT C E,ELBORN J S,RAMSEY B W.Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR[J].N Engl J Med,2015,373(18):1783-1784.
[24] KEREM E,KONSTAN MW,De BOECK K,et al.Ataluren for the treatment of nonsense-mutation cystic fibrosis:a randomized,double-blind,placebo-controlled phase 3 trial[J].Lancet Respir Med,2014,2(7):539-547.
[25] ALTON E W,ARMSTRONG D K,ASHBY D,et al.Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis:a randomized,double-blind,placebo-controlled,phase 2b trial[J].Lancet Respir Med,2015,3(9):684-691. |
